You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

DEGARELIX

Showing 1 - 25 of 142
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Prostatic Adenocarcinoma Trial in Charleston (Docetaxel, Degarelix)

Active, not recruiting
  • Metastatic Prostatic Adenocarcinoma
  • Charleston, South Carolina
    Medical University of South Carolina
Jan 30, 2023

Metastatic Castration Sensitive Prostate Cancer Trial in New York (Degarelix, Ipilimumab, Radical Prostatectomy)

Active, not recruiting
  • Metastatic Castration Sensitive Prostate Cancer
  • Degarelix
  • +2 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Aug 4, 2022

Urothelial Carcinoma Bladder, Androgen Receptor Positive Trial in Providence (Degarelix, Gemcitabine/Cisplatin)

Not yet recruiting
  • Urothelial Carcinoma Bladder
  • Androgen Receptor Positive
  • Degarelix
  • Gemcitabine/Cisplatin
  • Providence, Rhode Island
    Lifespan Cancer Institute
May 1, 2023

Localized Prostate Carcinoma, Castration-Naive Prostate Cancer, Intermediate Risk Prostate Cancer Trial in Turku (Degarelix,

Not yet recruiting
  • Localized Prostate Carcinoma
  • +3 more
  • Degarelix
  • MRI-guided transurethral ultrasound ablation (TULSA)
  • Turku, Southwest Finland, Finland
    Turku University Hospital
Jun 14, 2023

Invasive Ductal Breast Carcinoma Trial in Clamart (Degarelix injection(s))

Completed
  • Invasive Ductal Breast Carcinoma
  • Degarelix injection(s)
  • Clamart, France
    Hôpital Antoine Béclère
Sep 26, 2022

Endometriosis Trial in Tirana, Sofia, Rome (degarelix, goserelin)

Completed
  • Endometriosis
  • Tirana, Albania
  • +2 more
Feb 10, 2022

Prostatic Hyperplasia, Prostate Cancer Trial in Turku (Prostate hyperplasia medication, LhRH-antagonist)

Recruiting
  • Prostatic Hyperplasia
  • Prostate Cancer
  • Turku, Finland
  • +1 more
Aug 17, 2023

Prostate Cancer Trial in New York (BMS-986218 and Degarelix, Degarelix)

Recruiting
  • Prostate Cancer
  • BMS-986218 and Degarelix
  • Degarelix
  • New York, New York
    Columbia University Irving Medical Center
Oct 27, 2021

Prostate Cancer Trial in Houston (177Lu rhPSMA-10.1, Degarelix)

Not yet recruiting
  • Prostate Cancer
  • 177Lu rhPSMA-10.1
  • Degarelix
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2023

Leukemia, Multiple Myeloma, Myelodysplastic Syndrome Trial in New York (biological, procedure, radiation, drug)

Active, not recruiting
  • Leukemia
  • +3 more
  • Palifermin
  • +6 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jan 23, 2023

Prostate Cancer, Prostatic Adenocarcinoma Trial in New York (degarelix injection, androgen deprivation therapy)

Active, not recruiting
  • Prostate Cancer
  • Prostatic Adenocarcinoma
  • degarelix injection
  • androgen deprivation therapy
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Feb 28, 2022

Prostate Cancer Trial in Madison (Docetaxel, Degarelix, Bicalutamide)

Completed
  • Prostate Cancer
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
Sep 12, 2022

Prostate Cancer Trial (ADT, Enzalutamide, Talazoparib)

Not yet recruiting
  • Prostate Cancer
  • (no location specified)
May 15, 2023

FIRMAGON Intensive Drug Monitoring Protocol

Recruiting
  • Prostate Cancer
  • FIRMAGON Cohort
  • Beijing, China
    China Primary Healthcare Foundation
Dec 20, 2021

Stage III Prostate Adenocarcinoma AJCC v7, Stage III Prostate Cancer AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7 Trial in

Completed
Has Results
  • Stage III Prostate Adenocarcinoma AJCC v7
  • +3 more
  • Abiraterone Acetate
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 15, 2021

Radiation Therapy for Bladder Cancer

Recruiting
  • Bladder Cancer
  • +2 more
  • Degarelix
  • Aarhus, Denmark
    Aarhus University Hospital
Aug 5, 2022

Prostate Cancer Trial in United States (Abiraterone acetate, Abiraterone acetate plus degarelix, Degarelix)

Completed
Has Results
  • Prostate Cancer
  • Abiraterone acetate
  • +2 more
  • Chicago, Illinois
  • +15 more
Oct 25, 2021

Metastatic Prostate Cancer in Pirkanmaa Hospital District in

Not yet recruiting
  • Metastatic Castration Sensitive Prostate Cancer (mCSPC)
  • Metastatic Castration Resistant Prostate Cancer (mCRPC)
  • (no location specified)
Jan 17, 2023

Male Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma Trial in Boston

Not yet recruiting
  • Male Breast Cancer
  • +2 more
  • Boston, Massachusetts
  • +1 more
Aug 12, 2022

Menopause, Estrogen Deficiency, Women Trial in Aurora (GnRH antagonist)

Recruiting
  • Menopause
  • +3 more
  • GnRH antagonist
  • Aurora, Colorado
    University of Colorado Denver Anschutz Medical Campus
Jun 9, 2022

Prostate Cancer Trial in Baltimore (DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue)

Not yet recruiting
  • Prostate Cancer
  • Baltimore, Maryland
    Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Cen
Sep 22, 2023

Menopause, Obesity, Abdominal, Aging Trial in Aurora (GnRH antagonist, Estrogen Product, Placebo estradiol)

Recruiting
  • Menopause
  • +3 more
  • GnRH antagonist
  • +3 more
  • Aurora, Colorado
    University of Colorado - Anschutz Medical Campus
Oct 19, 2022

Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer Trial in Boston (Darolutamide, Abemaciclib, GNRH-A

Not yet recruiting
  • Metastatic Prostate Cancer
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Nov 14, 2022

Obesity, Fertility Trial in Aurora (Degarelix (GnRH antagonist), recombinant FSH, Cetrorelix)

Completed
Has Results
  • Obesity
  • Fertility
  • Degarelix (GnRH antagonist)
  • +2 more
  • Aurora, Colorado
    University of Colorado Clinical and Translational Research Cente
Mar 15, 2022

Prostate Cancer Trial in Madison (Degarelix, pTVG-AR, Nivolumab)

Recruiting
  • Prostate Cancer
  • Degarelix
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
Jul 6, 2022